Kellsye P Fabian

11PUBLICATIONS
16CO-AUTHORS
Molecular targetsCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 01, 2026
PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

|Dec 19, 2025
The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803.

Cailyn A Lee, Jeffrey Schlom, James W Hodge

|Nov 07, 2025
TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment.

Margaret R Pruitt, Kellsye P Fabian, Jung-Min Lee

|Oct 28, 2025
Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models.

Francesca Rosato, Ginette Santiago-Sanchez, Kellsye P Fabian

|Oct 24, 2024
Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models.

Kellsye P Fabian, Ginette Santiago-Sanchez, Michelle R Padget

|Feb 02, 2024
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance.

Ginette S Santiago-Sánchez, Kellsye P Fabian, James W Hodge

Pageof 2

Frequent Collaborators

11 joint publications

James W Hodge

4 joint publications

Jeffrey Schlom

4 joint publications

Ginette Santiago-Sánchez

3 joint publications

Clint Tanner Allen